Ignite Creation Date:
2025-12-24 @ 4:02 PM
Ignite Modification Date:
2025-12-24 @ 4:02 PM
Study NCT ID:
NCT03975166
Status:
COMPLETED
Last Update Posted:
2019-09-10
First Post:
2019-06-03
Is Possible Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
A Bioequivalence Study Between Fluticasone Propionate 100 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 Inhalation Powder/GSK in Healthy Volunteers
Sponsor:
Respirent Pharmaceuticals Co Ltd.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2019-05-21
Start Date Type:
ACTUAL
Primary Completion Date:
2019-06-25
Primary Completion Date Type:
ACTUAL
Completion Date:
2019-08-10
Completion Date Type:
ACTUAL
First Submit Date:
2019-06-03
First Submit QC Date:
None
Study First Post Date:
2019-06-05
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2019-09-09
Last Update Post Date:
2019-09-10
Last Update Post Date Type:
ACTUAL